Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.34 |
| ▸ | PDE4A | P27815 | 2/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | XPO1 | O14980 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20094349 | 0.85 | HRH4 (0.35) | TSHRPDE10AHRH4PDE4DPDE4A | |
| SCHEMBL20094276 | 0.83 | PDE4A (0.36) | PDE10AHRH4PDE4DPDE4APDE4B | |
| SCHEMBL20088553 | 0.83 | PDE4D (0.41) | PDE10AHRH4PDE4DPDE4APDE4B | |
| SCHEMBL20088561 | 0.80 | PDE10A (0.38) | PDE10AHRH4HTT | |
| SCHEMBL20088555 | 0.79 | KDM4E (0.36) | PDE10AHTT | |
| SCHEMBL20088556 | 0.78 | HRH4 (0.34) | PDE10AHRH4PDE4DPDE4APDE4B | |
| SCHEMBL20094307 | 0.78 | PDE10A (0.38) | PDE10AHTT | |
| SCHEMBL20088529 | 0.76 | HRH4 (0.36) | TSHRPDE10AHRH4PDE4DPDE4A | |
| SCHEMBL20088546 | 0.76 | PDE10A (0.42) | PDE10A | |
| SCHEMBL19560768 | 0.76 | PDE10A (0.51) | PDE10AHRH4PDE4DPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109963851-B | Fused bicyclic pyridine compounds and their use as AMPA receptor modulators | 詹森药业有限公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-3532477-B1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-26 | — | — | EP | disclosed |
| EP-3532477-B1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-26 | — | — | EP | disclosed |
| US-10087185-B2 | Fused bicylic pyridine compounds and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-02 | — | — | US | disclosed |
| WO-2018080917-A1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | WO | disclosed |
| US-20180111933-A1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-26 | — | — | US | disclosed |
| US-20180111933-A1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10087185-B2 | Fused bicylic pyridine compounds and their use as AMPA receptor modulators | GRIN1, GRIN3A, GRM1 | TSHR 721/4885PDE10A 1518/4885HRH4 291/4885 |
| US-20180111933-A1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN3A, GRM1 | TSHR 721/4885PDE10A 1518/4885HRH4 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.